恶性肿瘤免疫治疗后淋巴细胞表型及临床疗效的研究
肿瘤免疫治疗,,肿瘤免疫治疗；放射治疗；化学治疗；淋巴细胞表型；,临床疗效,1材料与方法,2结果,3讨论
摘 要 目的：研究免疫治疗和放、化疗对恶性肿瘤患者淋巴细胞表型的影响及其临床疗效的关系。方法： 42例晚期肿瘤患者中22例以放、化疗同时输注经共刺激的正常人外周血淋巴细胞(PBLs)进行免疫治疗，每周2次，8次为1疗程。另20例患者作为对照组，仅接受放、化疗。治疗前后用流式细胞仪检测淋巴细胞表型并观察临床症状。结果：放、化疗和免疫综合治疗组患者中15例(68.18%)的淋巴细胞表型明显改善，CD3+、CD4+治疗后明显升高，与治疗前比较P<0.05，CD95+升高，P<0.02，PS评分改善P<0.01；与20例对照组相比，治疗前各项无显著差异，治疗后CD4+升高，P<0.05，PS评分改善P<0.05；放、化疗联合免疫治疗组病人中有7例(31.82%)的淋巴细胞表型改善不明显，与治疗前及对照组比较，均无显著差异，但PS评分改善，P<0.02；对照组淋巴细胞表型与临床症状改变均不明显。结论：免疫治疗与放化疗联合治疗，可能有利于减轻放化疗的副作用，提高疗效，改善生活质量。关键词 肿瘤免疫治疗；放射治疗；化学治疗；淋巴细胞表型； 临床疗效
The relationship between lymphocyte phenotype and clinical efficacy in patients receiving immunotherapy combined with chemoradiotherapy
XIAO LianFeng, ZHU Yongxiang,QIU Liang,LUO Liqiong, LIN Yuexia
(1.Department of Surgery; 2. Institute of Biopharmacy Guangdong College of Pharmacy,Guangzhou 510224)
Abstract Objective: To observe the relationship between lymphocyte phenotype and clinical efficacy in cancer patients receiving immunotherapy combined with chemoradiotherapy. Methods: 42 patients were enrolled into the study. Among these patients, 22 received costimulated normal peripheral blood lymphocytes (PBLs) as well as chemoradiotherapy, and 20 patients received chemoradiotherapy only as control group. Immunotherapy was administrated biweekly, totally 8 times. Results: Among 22 patients receiving immmunotherapy, 15(68.18%) had lymphocyte phenotype change that was in accordance with symptom improvement, including elevation of CD3+, CD4+(P<0.05), CD95 (P<0.02); Among 22 patients receiving immmunotherapy, 7 (32.18%) had lymphocyte phenotype change that was in accordance with symptom improvement, but was not significant statistically. Control group had no symptom improvement without any change of lymphocyte phenotype. Conclusion: Immunotherapy combined with chemoradiotherapy could relieve the toxicity of chemoradiotherapy, enhance curative effect and improve life quality. ......
您现在查看是摘要页，全文长 9633 字符。